Recombinant Virus Vaccines

$1,342,916ZIAFY2022AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Paper 38536937 Paper 34232734 Paper 33688035 Paper 33442693 Paper 32019881 Paper 31145755 Paper 30778066 Paper 30541829 Paper 29869530 Paper 29669026 Paper 29257056 Paper 29237847 Paper 29021394 Paper 28968759 Paper 28721397 Paper 28588133 Paper 28060405 Paper 28027665 Paper 27683750 Paper 27466414 Paper 27006959 Paper 26528782 Paper 26528781 Paper 26116502 Paper 25875843 Paper 25874723 Paper 25653428 Paper 24920805 Paper 24403557 Paper 24243013 Paper 23928462 Paper 23677609 Paper 23583893 Paper 23390298 Paper 23049876 Paper 23035853 Paper 22234262 Paper 22178526 Paper 21864626 Paper 21628671 Paper 21377510 Paper 21282192 Paper 21085591 Paper 21076059 Paper 19995539 Paper 19654066 Paper 19450644 Paper 19420086 Paper 19224993 Paper 19135115 Paper 18808335 Paper 18793787 Paper 18160013 Paper 17579577 Paper 17360078 Paper 17201662 Paper 16725169 Paper 16472543 Paper 16409123 Paper 16267024 Paper 16083934 Paper 16023165 Paper 15780866 Paper 15731219 Paper 15725752 Paper 15650426 Paper 15380355 Paper 15367588 Paper 15315833 Paper 15249657 Paper 15242543 Paper 15242542 Paper 15161069 Paper 15096611 Paper 15070762 Paper 15014500 Paper 14963123 Paper 12970455 Paper 12869693 Paper 12477888 Paper 12097599 Paper 11983252 Paper 11752436 Paper 11393868 Paper 10775580 Paper 10684290 Patent 9879231 Patent 9453239 Patent 9254319 Patent 9133480 Patent 9133478 Patent 8916172 Patent 8623379 Patent 8124105 Patent 7867982 Patent 7795017 Patent 7560116 Patent 7303754

Abstract

There are many diseases for which there are no vaccines and others for which the vaccines are not optimal or have significant side effects. The objectives of this project are to develop new vectors, characterize viral antigens, determine targets of humoral and cell mediated immunity, and use this information to develop candidate vaccines. Live recombinant viral vaccines, DNA vaccines and recombinant protein vaccines are being developed. The attenuated vaccine vector known as modified vaccinia virus Ankara (MVA) was derived by extensively passaging the parental strain of vaccinia virus Ankara in chick embryo fibroblasts and is unable to replicate in most mammalian cells. The MVA host range restriction is exceptional in that synthesis of the abundant viral proteins appears unaffected, but morphogenesis of virus particles is abortive. Use of MVA for SARS-CoV-2 vaccines is described in another project. In previous studies, we demonstrated that three vaccinia virus proteins induce neutralizing antibodies that protect against vaccinia virus and monkeypox virus infections in mice and non-human primates. Further studies to improve vaccine response are in progress.

View original record on NIH RePORTER →